Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended		39 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Cash flows from operating activities:
Net loss	$ (2,316,000)	$ (9,900,000)	$ (17,904,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	226,000	274,000	676,000
Stock-based compensation expense	2,203,000	2,985,000	6,716,000
Conversion of ordinary shares to founders shares	2,037,000	2,804,000	4,841,000
Derivative liability	74,000	6,000	59,000
Warrant amendment expense	734,000		734,000
Issuance of common stock to consultants	125,000		1,146,000
Gain on bargain purchase	(6,444,000)		(6,444,000)
Loss on extinguishment of debt		549,000	549,000
Decrease in buy-back liability	(150,000)		(150,000)
Changes in operating assets and liabilities:
(Increase) decrease in other current assets	(10,000)	256,000	(31,000)
Increase in accounts payable and accrued liabilities	440,000	635,000	2,738,000
Increase (decrease) due to related parties	192,000	(223,000)	571,000
Increase in other accrued liabilities	22,000	23,000	54,000
Increase in grant payable	41,000	234,000	516,000
Net cash used in operating activities	(2,826,000)	(2,906,000)	(5,929,000)
Cash acquired in merger	292,000		292,000
Change in restricted cash	36,000	(58,000)	(48,000)
Investment in Pre-Merger Immune Pharmaceuticals Inc.	(1,598,000)		(1,598,000)
Purchase of property and equipment		(27,000)	(43,000)
Purchase of intangible assets			(520,000)
Net cash used in investing activities	(1,270,000)	(85,000)	(1,917,000)
Cash flows from financing activities:
Proceeds from issuance of shares, net of issuance costs	4,368,000	649,000	8,007,000
Issuance of short-term loan	86,000		86,000
Issuance of convertible loans			266,000
Repayment of loans	(36,000)	668,000	(96,000)
Net cash provided by financing activities	4,418,000	1,317,000	8,263,000
Net increase (decrease) in cash and cash equivalents	322,000	(1,674,000)	417,000
Cash and cash equivalents at beginning of year	95,000	1,792,000
Cash and cash equivalents at end of period	417,000	118,000	417,000
Supplemental disclosure of cash flow information:
Cash paid for interest	44,000		57,000
Cash paid for income taxes	3,000		3,000
Supplemental disclosure of non-cash financing activities:
Deemed dividend	(932,000)		(932,000)
Intangible assets acquired in non-monetary exchange		436,000	3,818,000
Assets Acquired [Member]
Merger between Immune Pharmaceuticals Inc. and Immune Pharmaceuticals Ltd.:
Assets Acquired	377,000		377,000
Fair value of other merger liabilities assumed	4,814,000		4,814,000
Fair value of investment and related party liability assumed	1,598,000		1,598,000
Fair value of deferred tax liability assumed	10,870,000		10,870,000
In Process Research and Development Acquired [Member]
Merger between Immune Pharmaceuticals Inc. and Immune Pharmaceuticals Ltd.:
Assets Acquired	27,500,000		27,500,000
Senior Secured Term Loan Assumed [Member]
Merger between Immune Pharmaceuticals Inc. and Immune Pharmaceuticals Ltd.:
Fair value of senior secured term loan assumed	$ 4,442,000		$ 4,442,000